文献速递乳腺癌

卵巢抑制下芳香化酶抑制剂对比他莫昔芬治疗绝经前雌激素受体阳性早期乳腺癌:四项随机试验7030例患者个体数据荟萃分析

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
PubMed 文献 · Lancet Oncol · 2022-02-03

该研究对四项随机试验(ABCSG XII、SOFT、TEXT、HOBOE)共7030例接受卵巢抑制的绝经前ER阳性早期乳腺癌患者进行个体数据荟萃分析,比较芳香化酶抑制剂与他莫昔芬。芳香化酶抑制剂降低乳腺癌复发风险(RR 0.79,95%CI 0.69-0.90),主要获益见于0-4年,5年复发绝对风险降低3.2%。远处复发减少(RR 0.83,95%CI 0.71-0.97),但乳腺癌死亡率、无复发死亡和全因死亡率无显著差异,骨折更多。

要点

  • 芳香化酶抑制剂较他莫昔芬降低乳腺癌复发风险(RR 0.79,95%CI 0.69-0.90,p=0.0005)。
  • 0-4年复发率芳香化酶抑制剂组6.9% vs 他莫昔芬组10.1%,绝对降低3.2%(95%CI 1.8-4.5)。
  • 两组乳腺癌死亡率(RR 1.01,95%CI 0.82-1.24)、无复发死亡和全因死亡率无显著差异。

核心结论

  • 在接受卵巢抑制的绝经前ER阳性早期乳腺癌患者中,使用芳香化酶抑制剂较他莫昔芬降低乳腺癌复发风险,但乳腺癌死亡率无显著差异。

研究设计与样本

  • 对四项随机试验(ABCSG XII、SOFT、TEXT、HOBOE)的个体患者数据进行荟萃分析,纳入7030例1999年6月17日至2015年8月4日入组的ER阳性肿瘤患者。
  • 比较芳香化酶抑制剂(阿那曲唑、依西美坦或来曲唑)与他莫昔芬使用3或5年,所有患者接受卵巢抑制(戈舍瑞林或曲普瑞林)或卵巢消融。
  • 主要结局为乳腺癌复发(远处、局部区域或对侧)、乳腺癌死亡率、无复发死亡和全因死亡率,采用意向性治疗log-rank分析估计首次事件率比(RR)及其置信区间。

主要发现

  • 中位随访8.0年(IQR 6.1-9.3),芳香化酶抑制剂组乳腺癌复发率低于他莫昔芬组(RR 0.79,95%CI 0.69-0.90,p=0.0005)。
  • 主要获益见于0-4年(RR 0.68,99%CI 0.55-0.85,p<0.0001),5年复发风险绝对降低3.2%(95%CI 1.8-4.5),芳香化酶抑制剂组6.9% vs 他莫昔芬组10.1%。
  • 5-9年(RR 0.98,99%CI 0.73-1.33,p=0.89)及10年后未见进一步获益或获益丧失。
  • 远处复发芳香化酶抑制剂组低于他莫昔芬组(RR 0.83,95%CI 0.71-0.97,p=0.018)。
  • 乳腺癌死亡率(RR 1.01,95%CI 0.82-1.24,p=0.94)、无复发死亡(RR 1.30,95%CI 0.75-2.25,p=0.34)和全因死亡率(RR 1.04,95%CI 0.86-1.27,p=0.68)两组无显著差异。

关键数值与推荐

  • 芳香化酶抑制剂组乳腺癌复发率低于他莫昔芬组:RR 0.79(95%CI 0.69-0.90,p=0.0005)。
  • 0-4年复发率芳香化酶抑制剂组6.9% vs 他莫昔芬组10.1%,绝对降低3.2%(95%CI 1.8-4.5)。
  • 远处复发芳香化酶抑制剂组低于他莫昔芬组:RR 0.83(95%CI 0.71-0.97,p=0.018)。
  • 骨折芳香化酶抑制剂组6.4% vs 他莫昔芬组5.1%:RR 1.27(95%CI 1.04-1.54,p=0.017)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更长期随访以评估对乳腺癌死亡率的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For women with early-stage oestrogen receptor (ER)-positive breast cancer, adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors are more effective than tamoxifen in postmenopausal women but are ineffective in premenopausal women when used without ovarian suppression. We aimed to investigate whether premenopausal women treated with ovarian suppression benefit from aromatase inhibitors. METHODS: We did a meta-analysis of individual patient data from randomised trials comparing aromatase inhibitors (anastrozole, exemestane, or letrozole) versus tamoxifen for 3 or 5 years in premenopausal women with ER-positive breast cancer receiving ovarian suppression (goserelin or triptorelin) or ablation. We collected data on baseline characteristics, dates and sites of any breast cancer recurrence or second primary cancer, and dates and causes of death. Primary outcomes were breast cancer recurrence (distant, locoregional, or contralateral), breast cancer mortality, death without recurrence, and all-cause mortality. As distant recurrence invariably results in death from breast cancer several years after the occurrence, whereas locoregional recurrence and new contralateral breast cancer are not usually fatal, the distant recurrence analysis is shown separately. Standard intention-to-treat log-rank analyses estimated first-event rate ratios (RR) and their confidence intervals (CIs). FINDINGS: We obtained data from all four identified trials (ABCSG XII, SOFT, TEXT, and HOBOE trials), which included 7030 women with ER-positive tumours enrolled between June 17, 1999, and Aug 4, 2015. Median follow-up was 8·0 years (IQR 6·1-9·3). The rate of breast cancer recurrence was lower for women allocated to an aromatase inhibitor than for women assigned to tamoxifen (RR 0·79, 95% CI 0·69-0·90, p=0·0005). The main benefit was seen in years 0-4 (RR 0·68, 99% CI 0·55-0·85; p<0·0001), the period when treatments differed, with a 3·2% (95% CI 1·8-4·5) absolute reduction in 5-year recurrence risk (6·9% vs 10·1%). There was no further benefit, or loss of benefit, in years 5-9 (RR 0·98, 99% CI 0·73-1·33, p=0·89) or beyond year 10. Distant recurrence was reduced with aromatase inhibitor (RR 0·83, 95% CI 0·71-0·97; p=0·018). No significant differences were observed between treatments for breast cancer mortality (RR 1·01, 95% CI 0·82-1·24; p=0·94), death without recurrence (1·30, 0·75-2·25; p=0·34), or all-cause mortality (1·04, 0·86-1·27; p=0·68). There were more bone fractures with aromatase inhibitor than with tamoxifen (227 [6·4%] of 3528 women allocated to an aromatase inhibitor vs 180 [5·1%] of 3502 women allocated to tamoxifen; RR 1·27 [95% CI 1·04-1·54]; p=0·017). Non-breast cancer deaths (30 [0·9%] vs 24 [0·7%]; 1·30 [0·75-2·25]; p=0·36) and endometrial cancer (seven [0·2%] vs 15 [0·3%]; 0·52 [0·22-1·23]; p=0·14) were rare. INTERPRETATION: Using an aromatase inhibitor rather than tamoxifen in premenopausal women receiving ovarian suppression reduces the risk of breast cancer recurrence. Longer follow-up is needed to assess any impact on breast cancer mortality. FUNDING: Cancer Research UK, UK Medical Research Council.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022. PMID: 35123662. doi:10.1016/S1470-2045(21)00758-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。